Century Therapeutics, Inc. (IPSC)

2.11USD +0.96% (+0.02)

Over 6M: -28.2%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

2 2.5 3
Mar Apr May Jun Jul Aug Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '23 — Operating Income: -35.6M Q4 '23 — Operating Income: -43.8M Q1 '24 — Operating Income: -31.3M Q2 '24 — Operating Income: -34.8M Q3 '24 — Operating Income: -34.8M Q4 '24 — Operating Income: -37.3M Q1 '25 — Operating Income: 74.2M Q2 '25 — Operating Income: -34.7M Q3 '25 — Operating Income: -36.1M Q4 '25 — Operating Income: -20.7M Q1 '26 — Operating Income: -23.7M Q2 '26 — Operating Income: -36.5M -25M 0 25M 50M 75M
Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Gross Profit Operating Income

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

2.1
OE margin -85.4%
Oper. margin -107.2%
ROIC -82.1%
Accruals -8.0%
EBITDA margin -98.3%
FCF margin -80.3%
OCF margin -79.5%
Profit margin -100.6%
ROA -38.3%
ROCE -43.0%
ROE -47.3%
Gross margin —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

5.7
EV/Sales 2.4×
EV/OE -2.8×
P/C 3.2×
P/B 1.6×
FCF yield -22.9%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

4.5
RPO / sales 1.0×
RPO growth -0.011%
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.2
ND/EBITDA 0.46
Cash runway 1.4 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 8.3×
F-score 3.9 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.6
Sales/sh Y/Y +1405.1%
Shares change +10.1%
Sales Q/Q -100.0%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.